Anthera Pharmaceuticals, Inc.

OTCPK:ANTH Stock Report

Market Cap: US$5.2k

Anthera Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Anthera Pharmaceuticals's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Mar 2018

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How Anthera Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ANTH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 180-2590
31 Dec 170-2980
30 Sep 170-35100
30 Jun 170-54110
31 Mar 170-68120
31 Dec 160-66110
30 Sep 162-5990
30 Jun 163-4590
31 Mar 163-3980
31 Dec 153-3580
30 Sep 151-3570
30 Jun 151-3170
31 Mar 150-2970
31 Dec 140-3070
30 Sep 140-316-10
30 Jun 140-307-6
31 Mar 140-3170

Quality Earnings: Insufficient data to determine if ANTH has high quality earnings.

Growing Profit Margin: Insufficient data to determine if ANTH's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ANTH's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare ANTH's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if ANTH's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: ANTH has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies